findmyKOL
Clinical trialNCT06343805RecruitingPhase 1Interventional

A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

SponsorAjax Therapeutics, Inc.Enrollment76PET-MFPMFPPV-MFPost-Essential Thrombocythemia MyelofibrosisPost-Polycythemia Vera MyelofibrosisPrimary Myelofibrosis
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

21 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

France
  • Ap-Hp Hopital Saint-Louis

    Paris, France

    Recruiting
Italy
  • Irccs Azienda Ospedaliero-Universitaria Di Bologna - Policlinico Di Sant Orsola

    Bologna, Italy, Italy

    Not, yet, recruiting
  • Fondazione Irccs Ca' Granda Ospedale Maggiore Policlinico

    Milan, Italy, Italy

    Not, yet, recruiting
Spain
  • Hospital General Universitario Gregorio Maranon

    Madrid, Spain, Spain

    Recruiting
  • Hospital Clinic Barcelona

    Barcelona, Spain

    Recruiting
  • Hospital Universitario Ramon Y Cajal

    Madrid, Spain

    Recruiting
United Kingdom
  • Guy'S Hospital

    London, UK, United Kingdom

    Not, yet, recruiting
  • Genesis Cancer Care Uk Limited - Oxford

    Oxford, UK, United Kingdom

    Not, yet, recruiting
United States
  • Stanford Cancer Institute

    Palo Alto, California, United States

    Recruiting
  • Moffitt Cancer Cancer Center

    Tampa, Florida, United States

    Recruiting
  • University of Kansas Medical Center

    Kansas City, Kansas, United States

    Recruiting
  • Dana Farber Cancer Institute

    Boston, Massachusetts, United States

    Recruiting
  • Massachusetts General Hospital

    Boston, Massachusetts, United States

    Recruiting
  • University of Michigan

    Ann Arbor, Michigan, United States

    Recruiting
  • Washington University School of Medicine

    St Louis, Missouri, United States

    Recruiting
  • David H. Koch Center for Cancer Care at Memorial Sloan Kettering

    New York, New York, United States

    Recruiting
  • Icahn School of Medicine at Mount Sinai

    New York, New York, United States

    Recruiting
  • Levine Cancer Institute

    Charlotte, North Carolina, United States

    Recruiting
  • University of Cincinnati

    Cincinnati, Ohio, United States

    Recruiting
  • the Ohio State University Comprehensive Cancer Center

    Columbus, Ohio, United States

    Recruiting
  • Md Anderson Cancer Center

    Houston, Texas, United States

    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
23 Oct 2024
Primary completion
15 Oct 2026
Completion
15 Feb 2027
Last update posted
12 May 2026
Registered enrollment
76
Registry id
NCT06343805

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.